About Mas-related G-protein coupled receptor member X3
Mas-related G-protein coupled receptor member X3 (MRGPRX3) is a protein
from Homo sapiens identified by UniProt accession
Q96LB0, 322 residues long.
MolForge cross-references it against 0 known binders and
22 disease associations.
Target properties
| Protein name | Mas-related G-protein coupled receptor member X3 |
| UniProt accession | Q96LB0 |
| Gene | MRGPRX3 |
| Organism | Homo sapiens |
| Length | 322 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (22)
Diseases linked to this target (Open Targets).
- neutrophil count · score 0.27
- leukocyte count · score 0.20
- myeloid white cell count · score 0.19
- mean corpuscular volume · score 0.07
- Recurrent infection due to specific granule deficiency · score 0.04
- neutrophil immunodeficiency syndrome · score 0.04
- hepatorenocardiac degenerative fibrosis · score 0.04
- renal cysts and diabetes syndrome · score 0.04
- Mayer-Rokitansky-Kuster-Hauser syndrome · score 0.03
- renal hypodysplasia/aplasia 3 · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96LB0-F1 | alphafold | PREDICTED | 81.99 | — |
Amino-acid sequence (322 residues)
MDSTIPVLGT ELTPINGREE TPCYKQTLSF TGLTCIVSLV ALTGNAVVLW LLGCRMRRNA VSIYILNLVA ADFLFLSGHI ICSPLRLINI RHPISKILSP VMTFPYFIGL SMLSAISTER CLSILWPIWY HCRRPRYLSS VMCVLLWALS LLRSILEWMF CDFLFSGANS VWCETSDFIT IAWLVFLCVV LCGSSLVLLV RILCGSRKMP LTRLYVTILL TVLVFLLCGL PFGIQWALFS RIHLDWKVLF CHVHLVSIFL SALNSSANPI IYFFVGSFRQ RQNRQNLKLV LQRALQDTPE VDEGGGWLPQ ETLELSGSRL EQ
Explore Mas-related G-protein coupled receptor member X3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets